每周两次外用钙泊三醇/二丙酸倍他米松泡沫主动管理斑块状银屑病可延长缓解时间且52周耐受良好(PSO-LONG试验)
PSO-LONG III期试验纳入545例达到治疗成功的斑块状银屑病患者,随机接受每周两次主动管理(Cal/BD泡沫,n=272)或反应性管理(赋形剂泡沫,n=273),复发时均予Cal/BD泡沫每日一次4周救援。主动组首次复发中位时间56天 vs 反应组30天,1年内额外缓解41天(P<.001),年复发次数3.1 vs 4.8,Cal/BD泡沫耐受良好。
要点
- 每周两次Cal/BD泡沫主动管理较反应性管理显著延长首次复发中位时间(56天 vs 30天)。
- 主动管理组1年内额外获得41天缓解(P<.001),年复发次数更低(3.1 vs 4.8)。
- Cal/BD泡沫每周两次长期主动管理52周耐受良好。
核心结论
- 每周两次Cal/BD泡沫主动管理斑块状银屑病在延长缓解和减少复发方面优于反应性管理,且52周耐受良好。
研究设计与样本
- III期随机双盲维持期试验(NCT02899962),含4周开放标签导入期(Cal/BD泡沫每日一次)和52周维持期。
- 545例达到治疗成功(PGA「清除」/「几乎清除」且较基线改善≥2级)的患者随机至主动管理组(Cal/BD泡沫,n=272)或反应性管理组(赋形剂泡沫,n=273),均每周两次用药。
- 复发时予Cal/BD泡沫每日一次4周救援治疗;主要终点为首次复发时间(PGA「轻度」或更差)。
主要发现
- 首次复发中位时间:主动组56天,反应组30天。
- 主动组较反应组1年内额外缓解41天(P<.001)。
- 每年暴露复发次数:主动组3.1次,反应组4.8次。
- Cal/BD泡沫耐受良好。
关键数值与推荐
- 治疗成功定义为PGA「清除」/「几乎清除」且较基线改善≥2级。
- 复发定义为PGA「轻度」或更差。
- 救援方案为Cal/BD泡沫每日一次持续4周。
临床怎么用
- 对达到治疗成功的斑块状银屑病患者,可考虑每周两次Cal/BD泡沫主动管理以延长缓解、减少复发。
- 复发时采用Cal/BD泡沫每日一次4周救援治疗。
局限性
- 维持期脱落率53.9%,虽在预期范围内但给统计分析带来挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Topical psoriasis treatment relies on a reactive rather than a long-term proactive approach to disease relapse. OBJECTIVE: Assess long-term efficacy and safety of proactive psoriasis management with twice-weekly calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam. METHODS: Phase III trial (NCT02899962) included a 4-week open-label lead-in phase (Cal/BD foam once daily) and a 52-week, randomized, double-blind, maintenance phase. A total of 545 patients achieved treatment success (physician's global assessment "clear"/"almost clear," ≥2-grade improvement from baseline) and were randomized to proactive management (Cal/BD foam; n = 272) or reactive management (vehicle foam; n = 273) twice-weekly, with rescue treatment of Cal/BD foam once daily for 4 weeks upon relapse. Primary endpoint was time to first relapse (physician's global assessment "mild" or higher). RESULTS: A total of 251 randomized patients (46.1%) completed the trial. Median time to first relapse was 56 days (proactive) and 30 days (reactive). Patients in the proactive group had an additional 41 days in remission compared with the reactive group over 1 year (P < .001). Number of relapses per year of exposure was 3.1 (proactive) and 4.8 (reactive). Cal/BD foam was well tolerated. LIMITATIONS: Maintenance phase dropout rate (53.9%) was within the expected range but provides challenges in statistical analysis. CONCLUSION: Long-term proactive management with Cal/BD foam demonstrated superior efficacy vs reactive management.
引用
- Lebwohl M, Kircik L, Lacour JP, et al. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). J Am Acad Dermatol. 2020. PMID: 32950546. doi:10.1016/j.jaad.2020.09.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。